atezolizumab + nab-paclitaxel

A combination immunochemotherapy regimen consisting of atezolizumab, a PD-L1 immune checkpoint inhibitor, and nab-paclitaxel, a chemotherapy drug that combines paclitaxel with albumin protein. This combination works through dual mechanisms: nab-paclitaxel provides cytotoxic effects against cancer cells while enhancing tumor-specific antigen release, and atezolizumab blocks PD-L1/PD-1 interactions to reverse T cell suppression. The combination was previously approved for PD-L1-positive metastatic triple-negative breast cancer (TNBC) based on the IMpassion130 trial, but this indication was voluntarily withdrawn by Roche in 2021 following discussions with the FDA.

Brand names

Tecentriq + Abraxane

Other names

nab-paclitaxelalbumin-bound paclitaxel